Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 Digestive Disease Week® (DDW)

Posted on by

– Two poster presentations of Mallinckrodt’s research for adults with HRS with rapid reduction in kidney function1 provide further insight into treatment with TERLIVAZ for appropriate patients – DUBLIN, May 18, 2024 /PRNewswire/ — Mallinckrodt plc, a global specialty pharmaceutical…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.